Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752505 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
A Phase 2 study of Fibromyalgia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 7
- Study locations
NCT00752505: Completed Phase 2 study of Fibromyalgia, sponsored by Pfizer.
NCT00752505 is a Phase 2 study of Fibromyalgia that has completed, run by Pfizer. The registered enrollment target is 89 participants, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (50% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00752505, a Phase 2 study of Fibromyalgia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cognitive function between fibromyalgia patients and matched control subjects.
Conditions Studied
Interventions
- DRUG Esreboxetine
Study Locations (7)
Florida
- Pfizer Investigational Site - Destin
- Pfizer Investigational Site - Fort Walton Beach
Michigan
- Pfizer Investigational Site - Ann Arbor
- Pfizer Investigational Site - Bingham Farms
Texas
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Dallas
Oklahoma
- Pfizer Investigational Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00752505 record still lists
NCT00752505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Esreboxetine is the first listed.
NCT00752505 lists 7 locations in 4 states (Florida, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT00752505 about?
NCT00752505 is a clinical study titled "A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.". The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cogniti...
What is the current status of trial NCT00752505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2008-08. Estimated completion is 2009-06.
What conditions does trial NCT00752505 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT00752505?
The interventions under investigation include: Esreboxetine (DRUG).
Who is sponsoring clinical trial NCT00752505?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00752505 being conducted?
This trial has 7 study locations across Florida, Michigan, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00752505's enrollment target sits among peer trials
89 36th of 76 higher than 41 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nitrous Oxide as Treatment for Fibromyalgia
RECRUITING · Phase 2
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Dextromethorphan in Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia